Proposed LCD DL39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS
Oncology
Government source· CMS / MACverify ↗HCPCS Level II code
Q5123 — Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
HCPCS Level IIVerified Sep 5, 2026
Medicare payment
—
No national Medicare fee schedule we hold prices Q5123 — the Physician Fee Schedule lists it with status indicator E (2026 file). CMS fee schedules ↗
Code definition
Code
Q5123
Code system
HCPCS Level II
Full description
Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
Policy activity for HCPCS Q5123
CLV Intelligence is tracking 2 policy changes that cite HCPCS Q5123 most recently on 2026-06-05, drawn from 1 LCD/NCD coverage update and 1 proposed LCD. The changes span Oncology. 1 is flagged critical or high priority.
- LCD/NCD coverage update
- 1
- proposed LCD
- 1
Counts reflect the source documents CLV has matched to HCPCS Q5123 to date; each links to the government publication that is authoritative. Monitored daily from CMS, the Federal Register, and Medicare Administrative Contractor publications.
Recent policy changes matched to Q5123
Matched to this code by CLV analysis of each policy. The linked source document is authoritative.
Search Q5123 across all alerts
Full history of CMS and MAC policy changes matched to this code.
Audit documentation
Building an audit file that includes HCPCS Q5123?
The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
See audit packs — $349One-time purchase · not a subscription
Get alerts when policy changes affect Q5123
Free weekly digest — no subscription required.
Get the free 90-day policy snapshot for your specialty
Free — no account required
See what CLV monitors for your specialty
Get a free 90-day sample snapshot — a PDF of every CMS and MAC policy change we tracked for your specialty and jurisdiction in the last quarter. Delivered instantly.
90-day windowPDF sample reportInstant download
By downloading, you agree to receive related policy update emails. You can unsubscribe at any time. Privacy policy